NCT04259450: Study to Assess AFM24 in Advanced Solid Cancers

NCT04259450
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER+, PR+
Other Mutations: EGFR
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Phase 1|Phase 2
Drug Category: Immunotherapy, Therapeutic Antibody

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older ¬† (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Patients must have been treated with at least 1 line of anticancer therapy & had progression on my recent line
Exclusions: 
https://ClinicalTrials.gov/show/NCT04259450

Comments are closed.

Up ↑